Recent Company News

• 01:41 PM ET Dec 05, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 07-Dec

• 03:30 AM ET Dec 05, 2025
  

  Japan's MHLW lists Santen Pharmaceutical and Bayer's aflibercept intraocular injection kit 40 mg/mL in National Health Insurance Drug Price List (¥1551.0000, 0)

• 11:07 AM ET Dec 04, 2025
  

  StreetAccount ESG Press Digest

• 02:35 AM ET Dec 04, 2025
  

  Evotec notes Bayer's trial initiation announcement; expects milestone payment upon first dosing of first study participant in early 2026 (€5.51, 0.00)

• 02:31 AM ET Dec 04, 2025
  

  Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome (€34.44, 0.00)

• 04:53 PM ET Dec 03, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:08 PM ET Dec 03, 2025
  

  Bayer announces results of pediatric study from pivotal clinical development program QUANTI for its low-dose MRI contrast agent gadoquatrane (€34.37, 0.00)

• 08:53 AM ET Dec 03, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:22 AM ET Dec 03, 2025
  

  StreetAccount Themes Headlines (3-Dec)

• 02:54 AM ET Dec 03, 2025
  

  StreetAccount Summary - European pre-market trading update